Cite
HARVARD Citation
Gökbuget, N. et al. (2020). Blinatumomab vs historic standard‐of‐care treatment for minimal residual disease in adults with B‐cell precursor acute lymphoblastic leukaemia. European journal of haematology. pp. 299-309. [Online].